Solid Biosciences (NASDAQ: SLDB) director details spouse RSU sale

Rhea-AI Filing Summary

Solid Biosciences Inc. director Ilan Ganot reported equity transactions related to spouse-held awards and updated his share holdings. On January 3, 2026, 2,994 restricted stock units held by his wife converted into 2,994 shares of common stock, reflecting one-for-one conversion of these awards. On January 5, 2026, 1,053 shares of common stock associated with his wife were sold at $5.43 per share to cover withholding taxes after the vesting of previously granted restricted stock units, and the filing notes these sales do not represent a discretionary trade by Ms. Ganot.

Following these transactions, 17,278 shares of common stock are reported as indirectly owned through his wife. The filing also reports 95,413 shares of common stock held directly by Mr. Ganot (including shares held jointly with Annie Ganot) and 19,394 shares held in the Ilan Ganot 2017 Irrevocable Trust, for which Adam and Annie Ganot serve as trustees.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ganot Ilan

(Last) (First) (Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN MA 02129

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/03/2026		M		2,994	A	(1)	18,331	I	Wife
Common Stock	01/05/2026		S		1,053(2)	D	$5.43	17,278	I	Wife
Common Stock								95,413	D(3)
Common Stock								19,394	I	See Footnote(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/03/2026		M			2,994	(5)	(5)	Common Stock	2,994	$0.00	2,994	I	Wife

Explanation of Responses:

1. Restricted stock units convert to common stock on a one-for-one basis.

2. This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The sales do not represent a discretionary trade by Ms. Ganot.

3. Represents 91,371 shares held by Mr. Ganot as an individual, and 4,042 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship.

4. Represents 19,394 shares held by Adam Ganot and Annie Ganot, and their successors, as the trustees for the Ilan Ganot 2017 Irrevocable Trust dated March 3, 2017.

5. On January 3, 2023 (the "Grant Date"), Ms. Ganot was granted 11,975 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date.

	/s/ by David Tyronne Howton as attorney-in-fact for Ilan Ganot	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did SLDB director Ilan Ganot report on this Form 4?

The Form 4 reports that 2,994 restricted stock units held by his wife converted into common stock on January 3, 2026, and that 1,053 shares of common stock associated with his wife were sold on January 5, 2026 at $5.43 per share to cover withholding taxes after vesting.

Were the SLDB share sales by the Ganot family discretionary trades?

No. The filing states that the 1,053-share sale on January 5, 2026 was made to cover withholding taxes following the vesting of previously granted restricted stock units and that these sales do not represent a discretionary trade by Ms. Ganot.

How do the restricted stock units reported by SLDB convert to common stock?

The filing explains that the restricted stock units convert to common stock on a one-for-one basis. In this case, 2,994 restricted stock units converted into 2,994 shares of Solid Biosciences common stock.

What are Ilan Ganot's reported direct and indirect SLDB share holdings after these transactions?

After the reported transactions, the Form 4 lists 95,413 shares of common stock held directly by Mr. Ganot (including shares held jointly with Annie Ganot), 17,278 shares indirectly owned through his wife, and 19,394 shares held in the Ilan Ganot 2017 Irrevocable Trust.

What does the SLDB Form 4 disclose about the Ilan Ganot 2017 Irrevocable Trust?

The Form 4 states that 19,394 shares of Solid Biosciences common stock are held by Adam Ganot and Annie Ganot, and their successors, as trustees for the Ilan Ganot 2017 Irrevocable Trust dated March 3, 2017.

What was the original grant for the restricted stock units linked to the 2026 SLDB transactions?

The filing notes that on January 3, 2023, Ms. Ganot was granted 11,975 restricted stock units, vesting in four equal installments on each anniversary of the grant date, which led to the 2,994-unit conversion reported for January 3, 2026.